Cyclosporin, combined with other agents, is an immunosuppressive agent approved for
prophylaxis of renal transplant rejection. In experimental studies, cyclosporin has
been shown to inhibit smooth muscle cell proliferation in the vascular response to
injury.
1
,
2
Similar experimental results have been observed with systemic use of rapamycin.
3
,
4
The aim of this clinical investigation was to test the hypothesis that systemic immunosuppression
therapy inhibits in-stent restenosis in renal transplant patients with coronary artery
disease treated with stenting.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury.Proc Natl Acad Sci USA. 1988; 85: 2303-2306
- A prescreening system for potential antiproliferative agents.Int J Cardiol. 1995; 51: 15-28
- Rapamycin inhibits vascular smooth muscle cell migration.J Clin Invest. 1996; 98: 2277-2283
- Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin.J Cardiovasc Phamacol. 1999; 33: 829-835
- Validation of the in vivo intravascular ultrasound measurement of in-stent neointimal hyperplasia volumes.J Am Coll Cardiol. 1998; 32: 794-799
- Morphometric analysis in three-dimensional intracoronary ultrasound.Am Heart J. 1996; 132: 516-527
- Explained and unexplained ischemic heart disease risk after renal transplantation.J Am Soc Nephrol. 2000; 11: 1735-1743
- The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation.J Am Coll Cardiol. 1998; 32: 584-589
- Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators.Circulation. 1999; 100: 799-806
- Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.N Engl J Med. 1999; 341: 319-327
- A randomized trial of corticosteroides for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty.Cathet Cardiovasc Diagn. 1989; 18: 227-231
- Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation.Am Heart J. 1999; 138: 60-63
- Effect of cyclosporine on arterial balloon injury lesions in cholesterol-clamped rabbits.Arterioscler Thromb Vasc Biol. 1999; 19: 1687-1694
- Three-dimensional intravascular ultrasonic volumetric quantification of stent recoil and neointimal formation of two new generation tubular stents.Am J Cardiol. 2000; 85: 135-139
- Sustained suppression of neointimal proliferation by sirolimus-eluting stents.Circulation. 2001; 104: 2007-2011
- Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.N Engl J Med. 2002; 346: 1773-1780
- Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention.Prog Cardiovasc Dis. 1997; 40: 141-158
- Nephrotoxicity of immunosuppressive drugs.Semin Nephrol. 1997; 17: 34-45
- Oral everolimus inhibits in-stent neointimal growth.Circulation. 2002; 106: 2379-2384
Article info
Publication history
Accepted:
February 21,
2003
Received in revised form:
February 21,
2003
Received:
November 21,
2002
Identification
Copyright
© 2003 Excerpta Medica Inc. Published by Elsevier Inc. All rights reserved.
